Aberrant activation of the Ras/Raf signaling cascade including the RAF/MEK/ERK and PI3K/AKT pathways—drives tumor proliferation and survival in Ras/Raf-mutant ovarian cancers. This evidence concerns the gene MAP2K7 and neoplasm.